Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 3/20 | 0.50 |
| ▸ | REN | P00797 | 2/20 | 0.48 |
| ▸ | CTSD | P07339 | 7/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | CASP9 | P55211 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyropeptin A SCHEMBL29843181 | 1.00 | CASP1 (0.50) | CASP1RENCTSDCASP3CASP7 | |
| Tyropeptin A SCHEMBL2808523 | 1.00 | CASP1 (0.50) | CASP1RENCTSDCASP3CASP7 | |
| SCHEMBL31010534 | 0.96 | CTSD (0.54) | CASP1RENCTSDCASP3CASP7 | |
| SCHEMBL9219464 | 0.96 | CTSD (0.54) | CASP1RENCTSDCASP3CASP7 | |
| SCHEMBL30467221 | 0.93 | MMP2 (0.48) | CASP1RENCTSDCASP3CASP7 | |
| SCHEMBL29537416 | 0.89 | CTSD (0.50) | CASP1CTSDPSMB5 | |
| SCHEMBL4325539 | 0.88 | PSMB5 (0.51) | RENPSMB5CTSB | |
| SCHEMBL4325541 | 0.88 | PSMB5 (0.51) | RENPSMB5CTSB | |
| SCHEMBL29369754 | 0.86 | CHRNA1 (0.52) | CASP1RENCASP3CASP7CASP9 | |
| SCHEMBL27787422 | 0.85 | CTSD (0.55) | RENCTSDCASP3CASP7PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313144-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117355333-A | Combination comprising anti-TM 4SF1 antibody and immunotherapeutic agent and method of use thereof | 安吉克公司 | 2024-01-05 | — | — | CN | claimed |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-09-21 | — | — | US | claimed |
| WO-2022204565-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | ANGIEX, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-3432911-B1 | AGONISTS OF THE NEURONAL CALCIUM SENSOR 1 FOR TREATING WOLFRAM SYNDROME | INST NAT SANTE RECH MED (FR) | 2025-07-23 | — | — | EP | disclosed |
| EP-3512602-B1 | INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2024-03-27 | — | — | EP | disclosed |
| EP-4313144-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117355333-A | Combination comprising anti-TM 4SF1 antibody and immunotherapeutic agent and method of use thereof | 安吉克公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2023-03-07 | — | — | US | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20110300247-A1 | FLAXSEED LIGNAN COMPLEX AND ITS USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-12-08 | — | — | US | disclosed |
| US-20100239696-A1 | FLAXSEED LIGNAN COMPLEX, METHODS OF USING AMD COMPOSITIONS THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2008147563-A1 | FLAXSEED LIGNAN COMPLEX, METHODS OF USING AND COMPOSITIONS THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080213172-A1 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-7238659-B2 | Reducing axon degeneration with proteasome inhibitors | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060074028-A1 | Reducing axon degeneration with proteasome inhibitors | CHILDREN'S MEDICAL CENTER CORP | 2006-04-06 | — | — | US | disclosed |
| US-7012063-B2 | Reducing axon degeneration with proteasome inhibitors | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| WO-2005014783-A2 | REDUCING AXON DEGENERATION WITH PROTEASOME INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | CASP1 2693/4885REN 4594/4885CTSD 2575/4885 |
| US-20080213172-A1 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES | LAP3, DNPEP, ACE | CASP1 1869/4885REN 41/4885CTSD 96/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | CASP1 3796/4885REN 4855/4885CTSD 2319/4885 |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | TM9SF4, TM9SF2, TM9SF3 | CASP1 4752/4885REN 4785/4885CTSD 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.